Researchers at Okayama University have developed an assay that may benefit drug discovery for treating diabetes, Alzheimers and Parkinson’s disease. Their work is published in the Journal of Medicinal Chemistry. The assay relies on a synthetic compound that promotes faster screening with fewer resource requirements than existing methods.
The researchers templated the chemical structure of their synthetic compound 10, on the RXR activator CD3254. Using compound 10, investigators demonstrated they could detect RXR targeting ligand activity with standard fluorescence microplate readers, without the necessity of additional complicated processes.